171017-48-4

Usage

Uses

Used in Pharmaceutical Industry:
<2-(3-hydroxyphenyl)-4-thiazolyl>acetic acid ethyl ester is used as an intermediate for the synthesis of various drugs due to its potential biological activities and therapeutic effects.
Used in Drug Discovery and Development:
<2-(3-hydroxyphenyl)-4-thiazolyl>acetic acid ethyl ester is used as a valuable component in the development of new pharmaceuticals for treating a wide range of medical conditions, leveraging its anti-inflammatory, antimicrobial, and analgesic properties.
Used in Agricultural and Environmental Sciences:
<2-(3-hydroxyphenyl)-4-thiazolyl>acetic acid ethyl ester is studied for its potential applications in the field of agricultural and environmental sciences, possibly for its antimicrobial properties or other beneficial effects on the environment or agriculture.

Upstream product

• 638-07-3 ethyl (2-chloroaceto)acetate 
• 104317-54-6 3-hydroxybenzenecarbothioamide 
• 7133-90-6 2-hydroxythiobenzamide 
• 873-62-1 m-cyanophenol 

Downstream Products

• 171017-67-7 (6R,7R)-3-acetyloxymethyl-7-<2-(3-hydroxyphenyl)-4-thiazolyl>acetylamino-8-oxo-5-thia-1-azabicyclo<4.2.0>oct-2-ene-2-carboxylic acid diphenylmethyl ester 
• 171017-68-8 (6R,7R)-7-<2-(3-hydroxyphenyl)-4-thiazolyl>acetylamino-8-oxo-5-thia-1-azabicyclo<4.2.0>oct-2-ene-2-carboxylic acid diphenylmethyl ester 
• 171017-52-0 <2-(3-hydroxyphenyl)-4-thiazolyl>acetic acid 

Relevant academic research and scientific papers

7-substituted-amino-3-substituted-3-cephem-4-carboxylic acids

The invention provides compounds of the formula STR1 wherein X is CH2, S or O; R1 is a 3 position substituent such as hydrogen, hydroxy, halo, trifluoromethyl, C2 F5, C1 -C6 alkyl, C1 -C6 substituted alkyl, C1 -C6 alkenyl, C1 -C6 alkynyl, CH2 O(CO)R', CH2 O(CO)NH2, CO2 R', thio(C1 -C6)alkyl, thio(C1 C6)alkenyl, oxo(C1 -C6)alkyl, phosphine oxide, quaternary ammonium group, substituted or unsubstituted thiazolothio, or oxo(C1 -C6)alkenyl; wherein R' is hydrogen, C1 -C6 alkyl, or C1 -C6 alkenyl; R2 is hydrogen or a carboxy protecting group; R3 is STR2 (CH2)n ; wherein R6 is hydrogen Me, CH2 F, CF3, C2 H5, CH2 CH2 F, CH2 CF3, C2 F5, CH2 CO2 R', CH2 CONH2, C(Me)2 CO2 R', or C(Me)2 CONH2 ; and n is 0-5; R4 is STR3 wherein Z is O, S, NH, or CH2 ; Y is CH or N; and R7 is hydrogen, C1 -C6 alkyl, CONH2, or CO2 R'; and R5 is STR4 wherein R8 is CH, N, COH, CO(C1 -C6 alkyl) CSH, or CNH2 ; and R9 is R8 as defined; said R5 optionally substituted 1-4 times with halo, OH, SH, NH2, NO2, CH3, C2 H5, CO2 R', CONH2, SO3 H, or SO2 NHR'; and salts thereof. Also, pharmaceutical formulations and methods for treating bacterial infections in man or other animals using the above compounds are disclosed.

Synthesis and in Vitro Evaluation of New Cephalosporins Exhibiting Antimicrobial Activity Against Gram-Positive Bacteria, in Particular Methicillin-Resistant Staphylococci

The preparation and biological evaluation of 7β-acetamido>cephalosporins and 7β-acetamido>cephalosporins, 9a-o, substituted at the 3-position with acetyloxymethyl, chlorine, hydrogen, and methyl are described.Hantzsch's thiazole synthesis is employed to provide thiazoleacetic acids 5a-e, subsequently followed by Morpho CDI-assisted amidation to complete the synthesis of target cephalosporins 9a-o.These compounds display activity selectively against Gram-positive bacteria, but are inactive against most Gram-negative bacteria tested.Those with acetyloxymethyl at the 3-position, i.e., 9a, 9e, 9i, 9m, and 9o, exhibit activity with minimal inhibitory concentrations of 16 μg/mL or lower against four strains of methicillin-resistant staphylococci, namely Staphylococcus aureus X400 and S13E and Staphylococcus epidermidis 270 and 222.Notably, 9a displays an activity profile similar to that of vancomycin regarding its spectrum and potency.Key Words: Gram-positive bacteria; Methicillin-resistant staphylococci; Cephalosporin; Thiazole synthesis; Amidation.